{"id":500811,"date":"2020-08-06T15:06:02","date_gmt":"2020-08-06T15:06:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=500811"},"modified":"2020-08-06T15:06:02","modified_gmt":"2020-08-06T15:06:02","slug":"chronic-heart-failure-clinical-trial-insight-pipeline-assessment-emerging-drugs-and-companies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chronic-heart-failure-clinical-trial-insight-pipeline-assessment-emerging-drugs-and-companies-by-delveinsight_500811.html","title":{"rendered":"Chronic Heart Failure Clinical Trial Insight, Pipeline Assessment, Emerging Drugs and Companies by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Chronic Heart Failure Clinical Trial Insight, Pipeline Assessment, Emerging Drugs and Companies by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" alt=\"Chronic Heart Failure Clinical Trial Insight, Pipeline Assessment, Emerging Drugs and Companies by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>&#8220;Chronic Heart Failure Pipeline Insight, 2020&#8221;<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">(Albany, NY) Delveinsight has launched a new report on &#8220;<strong> Chronic Heart Failure Pipeline Insight, 2020&#8243;.<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-heart-failure-pipeline-insight\" target=\"_blank\"><strong>Chronic Heart Failure Pipeline Insight, 2020<\/strong><\/a>&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;<strong>Chronic Heart Failure&nbsp;<\/strong>market. A detailed picture of the&nbsp;<strong>Chronic Heart Failure&nbsp;<\/strong>pipeline landscape is provided, which includes the disease overview and&nbsp;<strong>Chronic Heart Failure&nbsp;<\/strong>treatment guidelines.<\/p>\n<p style=\"text-align: justify;\">The assessment part of the report embraces in-depth&nbsp;<strong>Chronic Heart Failure&nbsp;<\/strong>commercial assessment and clinical assessment of the&nbsp;<strong>Chronic Heart Failure&nbsp;<\/strong>pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology,&nbsp;<strong>Chronic Heart Failure&nbsp;<\/strong>collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key companies Covered<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Novartis AG<\/li>\n<li>Bayer AG<\/li>\n<li>Orion Corp<\/li>\n<li>Vifor Pharma Ltd<\/li>\n<li>Cytokinetics Inc<\/li>\n<li>GlaxoSmithKline Plc<\/li>\n<li>Eli Lilly and Co<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-heart-failure-pipeline-insight\">https:\/\/www.delveinsight.com\/sample-request\/chronic-heart-failure-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The&nbsp;<strong>Chronic Heart Failure&nbsp;<\/strong>report provides an overview of&nbsp;<em>therapeutic pipeline activity and therapeutic assessment of the products<\/em>&nbsp;by development stage, product type, route of administration, molecule type, and MOA type&nbsp;<em>for&nbsp;<\/em><strong>Chronic Heart Failure&nbsp;<\/strong>across the complete product development cycle, including all clinical and nonclinical stages.<\/li>\n<li>It comprises of&nbsp;<em>detailed profiles of&nbsp;<\/em><strong>Chronic Heart Failure&nbsp;<\/strong><em>therapeutic products<\/em>&nbsp;with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/li>\n<li>Detailed&nbsp;<strong>Chronic Heart Failure&nbsp;<\/strong><em>research and development progress and trial details<\/em>, results wherever available, are also included in the pipeline study.<\/li>\n<li><em>Coverage of dormant and discontinued pipeline project<\/em>s along with the reasons if available across&nbsp;<strong>Chronic Heart Failure<\/strong>.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-heart-failure-pipeline-insight\" target=\"_blank\"><strong>Chronic heart failure<\/strong><\/a>, otherwise known as congestive heart failure or heart failure, is&nbsp;<strong>an ongoing inability of the heart to pump enough blood through the body to ensure a sufficient supply of oxygen.<\/strong>&nbsp;The causes of the condition vary, but some of the most common risk factors include old age,&nbsp;diabetes,&nbsp;high blood pressure&nbsp;and being overweight. Chronic heart failure is most common in men.<\/p>\n<p style=\"text-align: justify;\">The most common symptoms of chronic heart failure include&nbsp;<strong>shortness of breath, tiredness, swelling of the legs and ankles, chest pain and a cough.<\/strong>&nbsp;It most commonly affects older people and people with other heart conditions and is typically treated with a combination of lifestyle and diet changes, and medications. Chronic heart failure is typically a long-term condition that gradually worsens over time. This is the feature that differentiates it from&nbsp;acute heart failure, which develops very suddenly. It cannot typically be cured, but symptoms can be managed effectively.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-heart-failure-pipeline-insight\">https:\/\/www.delveinsight.com\/sample-request\/chronic-heart-failure-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Questions Covered:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>What are the current options for&nbsp;<strong>Chronic Heart Failure<\/strong>&nbsp;treatment?<\/li>\n<li>How many companies are developing therapies for the treatment of&nbsp;<strong>Chronic Heart Failure<\/strong>?&nbsp;<\/li>\n<li>What are the principal therapies developed by these companies in the industry?<\/li>\n<li>How many therapies are developed by each company for the treatment of&nbsp;<strong>Chronic Heart Failure<\/strong>?<\/li>\n<li>How many&nbsp;<strong>Chronic Heart Failure&nbsp;<\/strong>emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of&nbsp;<strong>Chronic Heart Failure<\/strong>?<\/li>\n<li>Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?&nbsp;<\/li>\n<li>What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact&nbsp;<strong>Chronic Heart Failure&nbsp;<\/strong>market?&nbsp;<\/li>\n<li>Which are the dormant and discontinued products and the reasons for the same?<\/li>\n<li>What is the unmet need for current therapies for the treatment of&nbsp;<strong>Chronic Heart Failure<\/strong>?&nbsp;&nbsp;<\/li>\n<li>What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing&nbsp;<strong>Chronic Heart Failure<\/strong>&nbsp;therapies?&nbsp;<\/li>\n<li>What are the clinical studies going on for&nbsp;<strong>Chronic Heart Failure&nbsp;<\/strong>and their status?<\/li>\n<li>What are the results of the clinical studies and their safety and efficacy?&nbsp;<\/li>\n<li>What are the key designations that have been granted for the emerging therapies for&nbsp;<strong>Chronic Heart Failure<\/strong>?&nbsp;<\/li>\n<li>How many patents are granted and pending for the emerging therapies for the treatment of&nbsp;<strong>Chronic Heart Failure<\/strong>?&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-heart-failure-pipeline-insight\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/www.abnewswire.com\/uploads\/5a243a9b5c1f7b77c81f01dad0c9e28e.gif\" alt=\"\" width=\"392\" height=\"139\" \/><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>1. Report Introduction<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>2. Chronic Heart Failure&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">2.1. Overview<\/p>\n<p style=\"text-align: justify;\">2.2. History&nbsp;<\/p>\n<p style=\"text-align: justify;\">2.3. Chronic Heart Failure Symptoms<\/p>\n<p style=\"text-align: justify;\">2.4. Causes<\/p>\n<p style=\"text-align: justify;\">2.5.Pathophysiology<\/p>\n<p style=\"text-align: justify;\">2.6. Chronic Heart Failure Diagnosis&nbsp;<\/p>\n<p style=\"text-align: justify;\">2.6.1. Diagnostic Guidelines<\/p>\n<p style=\"text-align: justify;\"><strong>3. Chronic Heart Failure&nbsp;Current Treatment Patterns<\/strong><\/p>\n<p style=\"text-align: justify;\">3.1. Chronic Heart Failure Treatment Guidelines<\/p>\n<p style=\"text-align: justify;\"><strong>4. Chronic Heart Failure&nbsp;&#8211; DelveInsight&#8217;s Analytical Perspective<\/strong><\/p>\n<p style=\"text-align: justify;\">4.1. In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">4.1.1. Chronic Heart Failure&nbsp;companies collaborations, Licensing, Acquisition -Deal Value Trends<\/p>\n<p style=\"text-align: justify;\">4.1.1.1. Assessment Summary<\/p>\n<p style=\"text-align: justify;\">4.1.2. Chronic Heart Failure&nbsp;Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">4.1.2.1. Company-Company Collaborations (Licensing \/ Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">4.1.2.2. Company-University Collaborations (Licensing \/ Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">4.1.2.3. Chronic Heart Failure&nbsp;Acquisition Analysis<\/p>\n<p style=\"text-align: justify;\"><strong>5. Therapeutic Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">5.1. Clinical Assessment of Pipeline Drugs&nbsp;<\/p>\n<p style=\"text-align: justify;\">5.1.1. Assessment by Phase of Development<\/p>\n<p style=\"text-align: justify;\">5.1.2. Assessment by Product Type (Mono \/ Combination)<\/p>\n<p style=\"text-align: justify;\">5.1.2.1. Assessment by Stage and Product Type<\/p>\n<p style=\"text-align: justify;\">5.1.3. Assessment by Route of Administration<\/p>\n<p style=\"text-align: justify;\">5.1.3.1. Assessment by Stage and Route of Administration<\/p>\n<p style=\"text-align: justify;\">5.1.4. Assessment by Molecule Type<\/p>\n<p style=\"text-align: justify;\">5.1.4.1. Assessment by Stage and Molecule Type<\/p>\n<p style=\"text-align: justify;\">5.1.5. Assessment by MOA<\/p>\n<p style=\"text-align: justify;\">5.1.5.1. Assessment by Stage and MOA<\/p>\n<p style=\"text-align: justify;\">5.1.6. Assessment by Target<\/p>\n<p style=\"text-align: justify;\">5.1.6.1. Assessment by Stage and Target<\/p>\n<p style=\"text-align: justify;\"><strong>6. Chronic Heart Failure Late Stage Products (Phase-III)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>7. Chronic Heart Failure Mid Stage Products (Phase-II)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>8. Early Stage Products (Phase-I)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>9. Pre-clinical Products and Discovery Stage Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>10. Inactive Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>11. Dormant Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>12. Chronic Heart Failure Discontinued Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>13. Chronic Heart Failure&nbsp;Product Profiles<\/strong><\/p>\n<p style=\"text-align: justify;\">13.1. Drug Name: Company&nbsp;<\/p>\n<p style=\"text-align: justify;\">13.1.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.1.1.1. Product Overview<\/p>\n<p style=\"text-align: justify;\">13.1.1.2. Mechanism of action<\/p>\n<p style=\"text-align: justify;\">13.1.2. Research and Development<\/p>\n<p style=\"text-align: justify;\">13.1.2.1. Clinical Studies<\/p>\n<p style=\"text-align: justify;\">13.1.3. Product Development Activities<\/p>\n<p style=\"text-align: justify;\">13.1.3.1. Collaboration<\/p>\n<p style=\"text-align: justify;\">13.1.3.2. Agreements<\/p>\n<p style=\"text-align: justify;\">13.1.3.3. Acquisition&nbsp;<\/p>\n<p style=\"text-align: justify;\">13.1.3.4. Patent Detail<\/p>\n<p style=\"text-align: justify;\">13.1.4. Tabulated Product Summary<\/p>\n<p style=\"text-align: justify;\">13.1.4.1. General Description Table<\/p>\n<p style=\"text-align: justify;\">Detailed information in the report?&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>14. Chronic Heart Failure&nbsp;Key Companies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>15. Chronic Heart Failure&nbsp;Key Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>16. Dormant and Discontinued Products<\/strong><\/p>\n<p style=\"text-align: justify;\">16.1. Dormant Products<\/p>\n<p style=\"text-align: justify;\">16.1.1. Reasons for being dormant<\/p>\n<p style=\"text-align: justify;\">16.2. Discontinued Products&nbsp;<\/p>\n<p style=\"text-align: justify;\">16.2.1. Reasons for the discontinuation<\/p>\n<p style=\"text-align: justify;\"><strong>17. Chronic Heart Failure&nbsp;Unmet Needs<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>18. Chronic Heart Failure&nbsp;Future Perspectives<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>19. Chronic Heart Failure&nbsp;Analyst Review&nbsp;&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>20. Appendix<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>21. Report Methodology<\/strong><\/p>\n<p style=\"text-align: justify;\">21.1. Secondary Research<\/p>\n<p style=\"text-align: justify;\">21.2. Expert Panel Validation&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Request for Detailed TOC:&nbsp;<strong>https:\/\/www.delveinsight.com\/sample-request\/chronic-heart-failure-pipeline-insight<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=chronic-heart-failure-clinical-trial-insight-pipeline-assessment-emerging-drugs-and-companies-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/hemorrhoids-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/hemorrhoids-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/hemorrhoids-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=chronic-heart-failure-clinical-trial-insight-pipeline-assessment-emerging-drugs-and-companies-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Chronic Heart Failure Pipeline Insight, 2020&#8221; (Albany, NY) Delveinsight has launched a new report on &#8220; Chronic Heart Failure Pipeline Insight, 2020&#8243;. &nbsp; &#8220;Chronic Heart Failure Pipeline Insight, 2020&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/chronic-heart-failure-clinical-trial-insight-pipeline-assessment-emerging-drugs-and-companies-by-delveinsight_500811.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,423,413],"tags":[],"class_list":["post-500811","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/500811","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=500811"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/500811\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=500811"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=500811"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=500811"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}